1-3 of 3
Yan-Ou Yang
Close
Sort by
Journal Articles

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Sanjay Mohan, Stephen Oh, Jean-Jacques Kiladjian, Masahiro Takeuchi, Jason Gotlib, Ellen K. Ritchie, Taizo Shimomura, Paola Guglielmelli, Anthony M. Hunter, Francesca Palandri, Francoise Boyer, Alessandro Rambaldi, Takehiko Mori, Tomoki Ito, Betty Lamothe, Yan-Ou Yang, Yi Cui, Francis Seguy, Amanda McBride, Prithviraj Bose
Journal: Blood
Blood (2023) 142 (Supplement 1): 624.
https://doi.org/10.1182/blood-2023-179291
Published: 2023
Journal Articles

Characterization of INCB00928, a Potent and Selective ALK2 Inhibitor for the Treatment of Anemia

Yaoyu Chen, Matthew C. Stubbs, PhD, Michelle Pusey, Xiaoming Wen, Robert J. Collins, Kanishk Kapilashrami, Mark Rupar, Pramod Thekkat, Luping Lin, PhD, Kevin Bowman, Yan-ou Yang, Sharon Diamond, Swamy Yeleswaram, PhD, Sunkyu Kim, Holly K. Koblish, PhD, Yingnan Chen, Susan Wee, PhD BS
Journal: Blood
Blood (2020) 136 (Supplement 1): 52.
https://doi.org/10.1182/blood-2020-136138
Published: 2020
Journal Articles

LSD1 Inhibition Induces Fetal Hemoglobin Expression and Provides a Novel Therapeutic Approach to Sickle Cell Disease

Sang Hyun Lee, PhD, Maxim Soloviev, MDPhD, Yan Zhang, PhD, Valerie Roman, Gengjie Yang, Kevin Bowman, Krista Burke, Alexander Margulis, Sybil O'Connor, Yan-ou Yang, PhD, Liangxing Wu, PhD, Richard Wynn, PhD, Timothy Burn, PhD, Dana Shuey, PhD, Sharon Diamond, PhD, Wenqing Yao, PhD, Gregory Hollis, PhD, Swamy Yeleswaram, PhD, Alan Roberts, PhD, Reid Huber, PhD, Peggy Scherle, PhD, Bruce Ruggeri, PhD
Journal: Blood
Blood (2016) 128 (22): 2472.
https://doi.org/10.1182/blood.V128.22.2472.2472
Published: 2016